Dashboard MRSA
Repurposing candidates for MRSA
Methicillin-resistant Staphylococcus aureus
Approved medicines with AI-predicted activity ≥40% against MRSA, leaving out medicines that are already antimicrobials. Each is shown with what it is already used for. They are surfaced computationally for further investigation, not as treatments.
- AI-predicted activity ≥40%
- 860
- Existing antimicrobials set aside
- 117
- Needing review
- 72
- Repurposing candidates
- 671
Repurposing candidates for MRSA
AI prediction · nothing measuredAll 671 repurposing candidates for MRSA.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AmcinonideExisting use: Corticosteroids, potent (group III)57.4% AI-predicted activityagainst MRSANo documented evidence found
- RepotrectinibExisting use: Cancer, Neoplasm57.4% AI-predicted activityagainst MRSA17 registered studies
- Dihydroergotamine MesylateExisting use: Migraine disorder57.4% AI-predicted activityagainst MRSA21 registered studies
- Ergoloid MesylatesExisting use: Cardiovascular disease57.4% AI-predicted activityagainst MRSA2 registered studies
- Azelastine HydrochlorideExisting use: Allergic conjunctivitis, Allergic disease, Allergic rhinitis and 5 more57.2% AI-predicted activityagainst MRSA48 registered studies
- ErtugliflozinExisting use: Sodium-glucose co-transporter 2 (SGLT2) inhibitors57.1% AI-predicted activityagainst MRSA49 registered studies
- Pasireotide PamoateExisting use: Acromegaly, Pituitary-dependent Cushing's disease57.1% AI-predicted activityagainst MRSA1 registered study
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more57.1% AI-predicted activityagainst MRSA21 registered studies
- Asciminib HydrochlorideExisting use: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic myelogenous leukemia, Neoplasm57.0% AI-predicted activityagainst MRSANo documented evidence found
- Tepotinib HydrochlorideExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma57.0% AI-predicted activityagainst MRSA6 registered studies
- VericiguatExisting use: Cardiovascular disease, Heart failure57.0% AI-predicted activityagainst MRSA50+ registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more57.0% AI-predicted activityagainst MRSA19 registered studies
- Azilsartan KamedoxomilExisting use: Hypertension, Stroke56.9% AI-predicted activityagainst MRSA1 registered study
- AdagrasibExisting use: Neoplasm, Non-small cell lung carcinoma56.9% AI-predicted activityagainst MRSA40 registered studies
- Lomitapide MesylateExisting use: Familial hypercholesterolemia, Homozygous familial hypercholesterolemia, Hypercholesterolemia56.9% AI-predicted activityagainst MRSANo documented evidence found
- BuprenorphineExisting use: Chronic pain, Drug dependence, Opioid dependence and 4 more56.9% AI-predicted activityagainst MRSA50+ registered studies
- IbrutinibExisting use: Cancer, Chronic lymphocytic leukemia, Macroglobulinemia and 3 more56.9% AI-predicted activityagainst MRSA50+ registered studies
- SimvastatinExisting use: Abnormal circulating lipid concentration, Acute myocardial infarction, Cardiovascular disease and 6 more56.8% AI-predicted activityagainst MRSA50+ registered studies
- DienogestExisting use: Menorrhagia56.8% AI-predicted activityagainst MRSA50+ registered studies
- Leniolisib PhosphateExisting use: Inborn error of immunity56.8% AI-predicted activityagainst MRSANo documented evidence found
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia56.8% AI-predicted activityagainst MRSA6 registered studies
- Lurasidone HydrochlorideExisting use: Bipolar disorder, Bipolar I disorder, Schizophrenia56.8% AI-predicted activityagainst MRSA50+ registered studies
- Testosterone CypionateExisting use: Cancer, Hypogonadism, Hypogonadotropic hypogonadism and 5 more56.6% AI-predicted activityagainst MRSA50+ registered studies
- UbrogepantExisting use: Migraine disorder56.6% AI-predicted activityagainst MRSA24 registered studies